Replies to post #86440 on Biotech Values

[AlpineBV_Miller]

Only by comparison to historical statin data or comparisons internal to each arm between dosing.

[DewDiligence]

This trial design can address the biological feedback of LDL levels when you try to modulate HDL using the CETP inhibitor alone. This arm also allows the sponsor to determine if the CETP inhibitor alone brings LDL down into the target range for benefit…

But isn’t it odd for a phase-2b trial conducted by a Big Pharma in a large indication to not have a bona fide control arm?